Rafael Holdings (RFL-WT) reported fourth-quarter fiscal 2026 revenue of $244,000 and a net loss attributable to the company of $9.2 million, or $0.18 per share. The results covered the three months ended July 31, 2026.
For fiscal 2026, Rafael reported revenue of $874,000 and a net loss attributable to the company of $29.6 million, or $0.58 per share. Cash and cash equivalents totaled $22.1 million at July 31, 2026.
- Fourth-quarter revenue was $244,000, compared with $350,000 a year earlier.
- Fourth-quarter net loss attributable to Rafael was $9.2 million, compared with $12.1 million in the prior-year period.
- Fiscal 2026 research and development expense was $24.3 million, versus $12.8 million in fiscal 2025.
- Cyclo Therapeutics submitted an NDA on October 28, 2026, for remibetadex for Niemann-Pick Disease Type C.
